Raymond James Trust N.A. Sells 760 Shares of Novo Nordisk A/S (NYSE:NVO)

Raymond James Trust N.A. decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 0.8% during the 3rd quarter, Holdings Channel reports. The firm owned 100,341 shares of the company’s stock after selling 760 shares during the quarter. Raymond James Trust N.A.’s holdings in Novo Nordisk A/S were worth $11,948,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Natixis Advisors LLC boosted its position in shares of Novo Nordisk A/S by 2.7% during the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after purchasing an additional 80,070 shares in the last quarter. Zions Bancorporation N.A. boosted its position in shares of Novo Nordisk A/S by 57.0% during the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its holdings in Novo Nordisk A/S by 14.8% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after acquiring an additional 37,346 shares in the last quarter. Private Wealth Partners LLC boosted its holdings in Novo Nordisk A/S by 155.1% in the third quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock worth $3,953,000 after acquiring an additional 20,188 shares in the last quarter. Finally, Buckingham Capital Management Inc. bought a new position in Novo Nordisk A/S in the third quarter worth approximately $3,874,000. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $102.77 on Friday. The company has a market cap of $461.18 billion, a PE ratio of 33.26, a price-to-earnings-growth ratio of 1.32 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The business has a 50 day moving average price of $116.12 and a 200-day moving average price of $128.92. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Analyst Ratings Changes

NVO has been the topic of several recent research reports. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. Finally, BMO Capital Markets cut their price target on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $144.50.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.